AURISCO PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.62 CNY | -2.19% |
|
+1.95% | -4.65% |
| Jun. 25 | Aurisco Pharmaceutical Gets Approval for Convertible Bond Sale | MT |
| Apr. 28 | Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Aurisco Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The Company's main products are respiratory, cardiovascular, anti-infective and nervous system drugs, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
24.62
CNY
Average target price
31
CNY
Spread / Average Target
+25.91%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.65% | 1.41B | |
| +54.07% | 816B | |
| +38.59% | 634B | |
| -7.05% | 351B | |
| +15.44% | 323B | |
| +5.72% | 293B | |
| +13.40% | 238B | |
| +0.61% | 222B | |
| +13.24% | 218B | |
| +7.42% | 167B |
- Stock Market
- Equities
- 605116 Stock
- News Aurisco Pharmaceutical Co.,Ltd.
- Aurisco Pharmaceutical Gets Approval for Convertible Bond Sale
